**Delisted Monday, 07 July, 2014, for failing meet their on-going obligations and conditions required under the BSX Listing Regulations, Section I, Chapter 2, Regulation 2.24(1), (3) & (4). **

**TRADING SUSPENDED 13 JUNE, 2014**

RezGen 5, Limited, was originally incorporated under the name NeoMedigen, Inc., in the Province of New Brunswick Canada bearing registration number 664491 on 15 June, 2012. It was continued to Bermuda under NeoMedigen Limited on 24 April, 2013, bearing registration number 47643 and as evidenced by a Certificate of Continuance issued by the Registrar of Companies in Bermuda on 7 May 2013.

RezGen 5, Limited is a Bermuda based biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes, Alzheimer’s and cardiovascular diseases. RezGen 5, Limited is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  The company's headquarters are in Hamilton, Bermuda.